IPHA 20-F DEF-14A Report Dec. 31, 2022 | Alphaminr

Effective Date August 11, 2021

These terms and conditions govern your use of the website alphaminr.com and its related services.

These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.

Subscription

Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.

Fees

We will provide you with advance notice of any change in fees.

Usage

You represent that you are of legal age to form a binding contract. You are responsible for any activity associated with your account. The account can be logged in at only one computer at a time.
The Services are intended for your own individual use. You shall only use the Services in a manner that complies with all laws. You may not use any automated software, spider or system to scrape data from Alphaminr.

Limitation of Liability

Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.

TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.

If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.

INNATE PHARMA SA

20-Fs

20-F	Fiscal year ended Dec. 31, 2024
20-F	Fiscal year ended Dec. 31, 2023
20-F	Fiscal year ended Dec. 31, 2022
20-F	Fiscal year ended Dec. 31, 2021
20-F	Fiscal year ended Dec. 31, 2020
20-F	Fiscal year ended Dec. 31, 2019

Name: Innate Pharma SA <br /> CIK: 1598599 <br /> Filing Type: 20-F/A <br /> Report Date: 2022-12-31 <br /> Download URL: https://www.sec.gov/Archives/edgar/data/1598599/000162828023012160/inpha-20221231.htm <br />

TABLE OF CONTENTS

Part I : Gender Identity Part II : Demographic Background Item 7. Major Shareholders and Related Party Transactions Item 8. Financial Information Item 9. The Offer and Listing Item 10. Additional Information Item 11. Quantitative and Qualitative Disclosures About Market Risk Item 12. Description Of Securities Other Than Equity Securities Part II Item 13. Defaults, Dividend Arrearages and Delinquencies Item 14. Material Modifications To The Rights Of Security Holders and Use Of Proceeds Item 15. Controls and Procedures Item 16. Reserved Item 16A. Audit Committees Financial Expert Item 16B. Code Of Business Conduct and Ethics Item 16C. Principal Accountant Fees and Services Item 16D. Exemptions From The Listing Standards For Audit Committees Item 16E. Purchases Of Equity Securities By The Issuer and Affiliated Purchasers Item 16F. Change in Registrant S Certifying Accountant Item 16G. Corporate Governance Item 16H. Mine Safety Disclosure Part III Item 17. Financial Statements Item 18. Financial Statements Item 19. Exhibits Note 1:the Company

Exhibits

1.1* By-laws (status) of the registrant (English translation) 2.1 Form of Deposit Agreement F-1 333-233865 4.1 10/04/19 4.1 Co-Development and License Agreement between Innate Pharma S.A. and MedImmune Limited, dated April24, 2015, as amended to date. F-1 333-233865 10.1 09/20/19 4.3 Amendment and Restatement Agreement of the Collaboration and Option Agreement Relating to CD39, between Innate Pharma S.A. and MedImmune Limited, dated April 16, 2019. F-1 333-233865 10.3 09/20/19 4.4 Joint Research, Development, Option and License Agreement between Innate Pharma S.A. and Novo Nordisk A/S, dated March 28, 2006, as amended to date. F-1 333-233865 10.4 09/20/19 4.5 Finance Lease Agreement between Innate Pharma S.A. and Sogebail S.A., dated June9, 2008 (English translation). F-1 333-233865 10.5 09/20/19 4.6 Amendment to Finance Lease Agreement between Innate Pharma S.A. and Sogebail S.A., dated September29, 2016 (English translation). F-1 333-233865 10.6 09/20/19 12.1* Certificate of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 12.2* Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 13.1** Certification by the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 15.1 Consent of Deloitte Associs

* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.

FUND	NUMBER OF SHARES	VALUE ($)	PUT OR CALL

DIRECTORS	AGE	BIO	OTHER DIRECTOR MEMBERSHIPS

Owner	Position	Direct Shares	Indirect Shares